Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 14/20 | 0.68 |
| ▸ | AVPR1A | P37288 | 13/20 | 0.68 |
| ▸ | OXTR | P30559 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7341288 | 0.86 | AVPR2 (0.68) | AVPR2AVPR1AOXTR | |
| SCHEMBL8313809 | 0.85 | AVPR2 (0.69) | AVPR2AVPR1AOXTR | |
| SCHEMBL7333870 | 0.85 | AVPR2 (0.64) | AVPR2AVPR1AOXTRNPC1RAB9A | |
| SCHEMBL8316487 | 0.82 | AVPR1A (0.49) | AVPR2AVPR1AOXTR | |
| SCHEMBL7332865 | 0.81 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| SCHEMBL8318709 | 0.79 | AVPR2 (0.54) | AVPR2AVPR1ANPC1RAB9A | |
| SCHEMBL8819612 | 0.79 | AVPR2 (0.60) | AVPR2AVPR1AOXTR | |
| SCHEMBL8820611 | 0.78 | AVPR2 (0.59) | AVPR2AVPR1AOXTR | |
| SCHEMBL8314766 | 0.78 | AVPR2 (0.54) | AVPR2AVPR1AOXTR | |
| SCHEMBL8314000 | 0.78 | AVPR1A (0.56) | AVPR2AVPR1AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5968930-A | FOR TREATMENT AND/OR PREVENTION OF HYPERTENSION, CARDIAC INSUFFICIENCY, CORONARY VASOSPASM, CARDIAC ISCHEMIA, RENAL VASOSPASM, LIVER CIRRHOSIS, CONGESTIVE HEART FAILURE, NEPHROTIC SYNDROME, BRAIN EDEMA, CEREBRAL ISCHEMIA | AMERICAN CYANAMID COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| US-5968937-A | FOR TREATMENT AND/OR PREVENTION OF HYPERTENSION, CARDIAC INSUFFICIENCY, CORONARY VASOSPASM, CARDIAC ISCHEMIA, RENAL VASOSPASM, LIVER CIRRHOSIS, CONGESTIVE HEART FAILURE, NEPHROTIC SYNDROME, BRAIN EDEMA, CEREBRAL ISCHEMIA | AMERICAN CYANAMID COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| US-5624923-A | UROGENITAL AND CARDIOVASCULAR DISORDERS | AMERICAN CYANAMID COMPANY (US) | 1997-04-29 | — | — | US | disclosed |
| US-5516774-A | TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1996-05-14 | — | — | US | disclosed |